| abstract |
Treatments for conditions involving detrimental activity of the enzyme core 2 GIcNAc - T are provided using compounds of the formula (I) wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R 3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy- C1-6 -alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof |